Health Catalyst, Inc. (NASDAQ:HCAT) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. boosted its stake in Health Catalyst, Inc. (NASDAQ:HCAT) by 93.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 254,762 shares of the company’s stock after purchasing an additional 123,230 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.42% of Health Catalyst worth $1,801,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Legato Capital Management LLC increased its holdings in Health Catalyst by 3.7% in the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock valued at $622,000 after purchasing an additional 3,171 shares in the last quarter. Quest Partners LLC acquired a new stake in Health Catalyst in the 3rd quarter valued at $34,000. SG Americas Securities LLC increased its holdings in Health Catalyst by 21.7% in the 4th quarter. SG Americas Securities LLC now owns 27,382 shares of the company’s stock valued at $194,000 after purchasing an additional 4,874 shares in the last quarter. Franklin Resources Inc. increased its holdings in Health Catalyst by 5.8% in the 3rd quarter. Franklin Resources Inc. now owns 104,141 shares of the company’s stock valued at $857,000 after purchasing an additional 5,687 shares in the last quarter. Finally, Inspire Investing LLC increased its holdings in Health Catalyst by 14.2% in the 4th quarter. Inspire Investing LLC now owns 56,379 shares of the company’s stock valued at $399,000 after purchasing an additional 7,019 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $4.45 on Wednesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst, Inc. has a one year low of $3.76 and a one year high of $9.24. The company’s 50-day simple moving average is $5.32 and its 200-day simple moving average is $7.02. The stock has a market capitalization of $312.44 million, a price-to-earnings ratio of -3.30 and a beta of 1.41.

Insider Transactions at Health Catalyst

In other Health Catalyst news, Director Duncan Gallagher sold 4,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $6.98, for a total value of $31,410.00. Following the transaction, the director now owns 74,438 shares of the company’s stock, valued at $519,577.24. This trade represents a 5.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.51, for a total transaction of $39,119.59. Following the completion of the transaction, the chief operating officer now directly owns 91,253 shares in the company, valued at $685,310.03. This represents a 5.40 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 65,530 shares of company stock valued at $362,167. Insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on HCAT. Canaccord Genuity Group decreased their price objective on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 21st. Citigroup decreased their price objective on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, January 10th. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a research report on Wednesday, January 8th. Wells Fargo & Company decreased their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research report on Tuesday, January 21st. Finally, Piper Sandler decreased their price objective on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 11th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.27.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.